Takeda Pharmaceutical Ordered to Pay $885 Million for Antitrust Violations

On May 18, 2026, a jury in the U.S. District Court for the District of Massachusetts rendered a landmark verdict, finding Japanese pharmaceutical giant Takeda Pharmaceutical liable in an antitrust lawsuit and ordering it to pay $885 million in damages.

The case stems from a class action lawsuit filed in 2021 by multiple pharmacies, retailers, insurance providers, and healthcare funds. The lawsuit alleged that Takeda entered into a "pay-for-delay" agreement in 2014 – a common tactic used by brand-name drug manufacturers to block generic entry, whereby the brand-name manufacturer pays a generic company a substantial consideration in exchange for the generic’s agreement to abandon a patent challenge and delay its market entry, thereby maintaining monopoly pricing without facing competition.

In this case, the agreement among Takeda, Sucampo Pharmaceuticals (then its partner), and generic drugmaker Par Pharmaceutical stipulated that Par’s generic version would not be launched until January 2021. Under the agreement, this delay postponed the availability of cheaper generic drugs by six years. Moreover, the agreement included a complex profit-sharing mechanism: after the generic product entered the market, the first 50% of its profits were to be paid to the Takeda side, with this high sharing ratio to remain in effect if Par’s generic was the only generic on the market.

The jury awarded initial damages of 885 million ,covering compensation for the whole saleclass ,the end−pay or consumer class, and five retailers. However, this is far from the final amount. Under U.S. antitrust law, this award will be automatically trebled, pursuant to Section15 of Title15 of theU.S.Code, which provides that any person who has been injured in their business or property by conduct prohibited by the antitrust laws may sue and shall recover three fold the damages sustained, as well as the cost of the suit. This means that, once the violation is established, the damages will increase to approximately 885million, covering compensation for the whole saleclass, the end−pay or consumer class, and five retailers. However, this is far from the final amount. Under U.S. antitrustlaw, this award will be automatically trebled, pursuant  to Section 15 of Title 15 of the U.S. Code, which provides that any person who has been injured in their business or property by conduct prohibited by the antitrust laws may sue and shall recover three fold thedamagessustained,aswellasthecostofthesuit. This means that, once the violation is established, the damages will increase to approximately 2.65 billion.

Takeda responded swiftly, making clear that it will appeal and stating that the verdict is not currently enforceable as the case is still pending. Meanwhile, the license agreement for the drug at issue, Amitiza, expired in March 2024, and Takeda no longer markets the product. China Intellectual Property Lawyer Network will continue to follow further developments.